A Semi-Automated Technique Determining the Liver Standardized Uptake Value Reference for Tumor Delineation in FDG PET-CT
暂无分享,去创建一个
Kenji Hirata | Osamu Manabe | Sung-Cheng Huang | Nagara Tamaki | Koon-Pong Wong | Kentaro Kobayashi | Sung-Cheng Huang | Koon-Pong Wong | N. Tamaki | K. Hirata | Kentaro Kobayashi | Andrew Surmak | O. Manabe | A. Surmak
[1] S. Ben-Haim,et al. 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response* , 2008, Journal of Nuclear Medicine.
[2] S. Yang,et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[3] P. Grigsby,et al. Changes in cervical cancer FDG uptake during chemoradiation and association with response. , 2013, International journal of radiation oncology, biology, physics.
[4] B. C. Penney,et al. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. , 2013, Academic radiology.
[5] O. Belohlávek,et al. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma , 2012, Nuclear medicine communications.
[6] B. Loo,et al. Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal , 2013, The Journal of Nuclear Medicine.
[7] Nan-Tsing Chiu,et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. , 2012, Radiology.
[8] J Nucl Med , 2010 .
[9] Dorte Nielsen,et al. Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab , 2013, The Journal of Nuclear Medicine.
[10] Vladimir Y. Panin,et al. Fully 3-D PET reconstruction with system matrix derived from point source measurements , 2006, IEEE Transactions on Medical Imaging.
[11] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[12] Anthony C. Davison,et al. Bootstrap Methods and Their Application , 1998 .
[13] Y. Jhanwar,et al. The role of PET in lymphoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Jeong Hyun Lee,et al. Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis Measured by 18F-FDG PET/CT in Salivary Gland Carcinomas , 2013, The Journal of Nuclear Medicine.
[15] D. Jeon,et al. Initial Metabolic Tumor Volume Measured by 18F-FDG PET/CT Can Predict the Outcome of Osteosarcoma of the Extremities , 2013, The Journal of Nuclear Medicine.
[16] Yongxue Zhang,et al. Prognostic Predictive Value of Total Lesion Glycolysis From 18F-FDG PET/CT in Post-Surgical Patients With Epithelial Ovarian Cancer , 2013, Clinical nuclear medicine.
[17] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[18] Ora Israel,et al. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] R. Subramaniam,et al. Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. , 2013, Radiology.
[20] A. Iagaru,et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. , 2010, International journal of radiation oncology, biology, physics.
[21] R. Korn,et al. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib , 2012, Cancer medicine.
[22] R. Wahl,et al. A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck , 2012, Clinical Cancer Research.
[23] B. C. Penney,et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[24] David Dagan Feng,et al. Automated and Robust PERCIST-based Thresholding framework for whole body PET-CT studies , 2012, 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[25] W. Oyen,et al. 18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy , 2013, The Journal of Nuclear Medicine.
[26] Hao Wang,et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[27] T. Nagaoka,et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. , 2012, Radiology.
[28] T. Watabe,et al. Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors , 2012, The Journal of Nuclear Medicine.
[29] S. Holm. A Simple Sequentially Rejective Multiple Test Procedure , 1979 .
[30] Milan Sonka,et al. Automated measurement of uptake in cerebellum, liver, and aortic arch in full-body FDG PET/CT scans. , 2012, Medical physics.